CMS Explains “Newness” Criterion In Blincyto NTAP Discontinuation
Executive Summary
Amgen’s argument that continuing the Medicare new technology add-on payment for Blincyto would allow for more data to be collected failed to persuade US CMS.
You may also be interested in...
Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments
CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.
A Final Push For US Hepatitis C Eradication Plan In 2024
The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.
Menopausal Status Is Another Focus For US FDA Trial Inclusion Efforts
US FDA is emphasizing the need to assess the effects of menopause on drug safety and efficacy as a continuation of the agency’s efforts to encourage clinical trial sponsors to look more systematically for differences in clinical trial subpopulations.